1. Overexpression of Ephrin A3 Receptor in Canine Prostatic Carcinoma
   G. Hood et al, 2016, Journal of Comparative Pathology CrossRef
2. Tumor Protein D52 (TPD52)
   Yuyan Chen et al, 2016, Encyclopedia of Signaling Molecules CrossRef
3. Differential expression of EphA5 protein in gastric carcinoma and its clinical significance
   Wei Zhang et al, 2019, Oncology Letters CrossRef
4. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer
   Claudia Cava et al, 2018, International Journal of Molecular Sciences CrossRef
5. EPHA3 enhances macrophage autophagy and apoptosis by disrupting the mTOR signaling pathway in mice with endometriosis
   Hongmei Xu et al, 2019, Bioscience Reports CrossRef
6. The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
   Xiuzhi Duan et al, 2019, Journal of Clinical Laboratory Analysis CrossRef
7. Suppression of PC-1/PrLZ sensitizes prostate cancer cells to ionizing radiation by attenuating DNA damage repair and inducing autophagic cell death
   Zeng-Fu Shang et al, 2016, Oncotarget CrossRef
8. Tumor Protein D52 (TPD52)
   Yuyan Chen et al, 2018, Encyclopedia of Signaling Molecules CrossRef
9. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells
   Francesco La Rocca et al, 2017, Cellular Oncology CrossRef
10. High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival
    Baongoc Nasri et al, 2017, BMC Clinical Pathology CrossRef
11. PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability
    Lan Yu et al, 2015, Oncotarget CrossRef
12. Overexpression of p54nrb/NONO induces differentialEPHA6splicing and contributes to castration-resistant prostate cancer growth
    Ryuji Yamamoto et al, 2018, Oncotarget CrossRef
13. Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3
    Yali Zhao et al, 2015, PLOS ONE CrossRef
14. Germline copy number variation analysis in Finnish families with hereditary prostate cancer
    Virpi H. Laitinen et al, 2016, The Prostate CrossRef
15. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
    Rahul Aggarwal et al, 2022, Prostate Cancer CrossRef
16. Novel Nine-Exon AR Transcripts (Exon 1/Exon 1b/Exons 2–8) in Normal and Cancerous Breast and Prostate Cells
    Dong Hu et al, 2016, International Journal of Molecular Sciences CrossRef
17. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response
    Milad Ashrafizadeh et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef
18. The Hippo effector YAP1/TEAD1 regulates EPHA3 expression to control cell contact and motility
    Marwah M. Al-Mathkour et al, 2022, Scientific Reports CrossRef
19. Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics
    Max London et al, 2020, Molecular Biology Reports CrossRef